

# TALKING ABOUT NALOXONE

## WB4518

**PROGRAM DESCRIPTION:** This enduring activity is designed improve patient outcomes by increasing naloxone prescribing and communication practices surrounding naloxone.

### OBJECTIVES:

At the conclusion of the training, the participant should be able to:

1. List risk factors for opioid-related harms.
2. Select strategies for starting a conversation with patients about naloxone and educating them about the risk of overdose and the role of naloxone in preventing overdoses.
3. Identify how interprofessional care coordination to support offering of naloxone can reduce the risk of opioid overdose.
4. Describe how to communicate about naloxone in a caring, compassionate, and non-stigmatizing manner.

### FACULTY/ CREDENTIALS:

Christina A. Mikosz, MD, MPH  
Lead Medical Officer, Division of Overdose  
Prevention, National Center for Injury  
Prevention and Control

Molly Dowling, MPH, CHES  
Health Communications Specialist  
Division of Overdose Prevention  
National Center for Injury Prevention and  
Control

**ORIGINATION DATE:** May 25, 2022  
**EXPIRATION DATE:** May 25, 2024

### URL:

<https://www.cdc.gov/opioids/naloxone/training/index.html>

<b>HARDWARE/SOFTWARE:</b>	Computer Hardware; Internet Connection; Browser
<b>MATERIALS:</b>	None
<b>TARGET AUDIENCE:</b>	Physicians, Registered Nurses, Other health professionals
<b>PREREQUISITES:</b>	None
<b>FORMAT:</b>	This activity is <b>Web-based</b> .
<b>CONTACT INFORMATION:</b>	Division of Overdose Prevention, National Center for Injury Prevention and Control 800-232-4636,

#### ACCREDITATION STATEMENTS:



In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**CME:** The Centers for Disease Control and Prevention designates this **enduring** activity for a maximum of **1.5** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**CNE:** The Centers for Disease Control and Prevention designates this activity for **1.5** nursing contact hours.

**CEU:** The Centers for Disease Control and Prevention is authorized by IACET to offer **0.2** CEU's for this program.

**DISCLOSURE:** In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

## Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for **WB4518 - Talking about Naloxone** please visit [TCEO](#) and follow these [9 Simple Steps](#) before **05/25/2024**.

Complete the activity

Complete the Evaluation at [www.cdc.gov/GetCE](http://www.cdc.gov/GetCE)

Pass the posttest at **80%** at [www.cdc.gov/GetCE](http://www.cdc.gov/GetCE)

**FEES:** No fees are charged for CDC's CE activities.